Short communication

High glucocorticoid receptor expression in the sarcomatous versus carcinosomatous elements of Mullerian carcinosarcomas

Katherine C. Kurnit a,⁎, Meghan Steiner b, Ricardo R. Lastra c, S. John Weroha d,⁎, John Cursio f, Ernst Lengyel a,⁎, Gini F. Fleming b, Suzanne D. Conzen d

⁎ Corresponding author at: The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2050 Chicago, IL 60637.
E-mail address: kkurnit@bsd.uchicago.edu (K.C. Kurnit).

A R T I C L E  I N F O
Keywords:
Carcinosarcoma
Glucocorticoid receptor
Estrogen receptor
Progesterone receptor

A B S T R A C T
Glucocorticoid receptor can be associated with poor prognosis among a variety of solid tumors in the absence of other nuclear hormone receptors. Our objective was to characterize differences in glucocorticoid receptor (GR), estrogen receptor (ER), progesterone receptor (PR), and androgen receptor expression in the sarcomatous versus carcinosomatous components of ovarian and uterine carcinosarcomas. Eighteen patients diagnosed with Mullerian carcinosarcoma between May 2009 and August 2014 were included. Nuclear receptor expression was evaluated by immunohistochemistry using whole tissue specimens. Receptor expression was quantified using the H-score. Mean H-scores were compared between the sarcomatous and carcinosomatous components of tumors using Wilcoxon signed-rank tests. We found that GR expression was significantly higher in the sarcomatous components than in the carcinosomatous components of the cancers (mean H score 144.4 vs 38.9, p = 0.002). Conversely, ER (3.1 vs 63.1, p = 0.002) and PR (1.7 vs 47.2, p < 0.0001) expression were significantly decreased in the sarcomatous component compared to the carcinosomatous component. Androgen receptor expression was low overall (0 versus 2.8, p = 0.04). We hypothesize that GR-high, ER/PR-low expression is associated with epithelial to mesenchymal transition in the sarcomatous cells and may serve as a potential therapeutic target.

1. Introduction

Carcinosarcomas are rare and aggressive gynecologic malignancies defined by a biphasic tumor histology including both carcinosomatous and sarcomatous components (Berton-Rigaud et al., 2014). Mullerian carcinosarcomas have been reported to account for 5% or less of all ovarian and endometrial malignancies, but the survival outcomes are worse than for high grade serous and endometrioid tumors of the ovary and endometrium, respectively (Berton-Rigaud et al., 2014). Primary tumors with a greater proportion of sarcomatous histology—sometimes referred to as sarcoma-dominant—behave more aggressively than carcinosomatous tumors and carry a worse prognosis (Matsuoka et al., 2018). While carcinosarcomas were initially classified and treated as sarcomas, a growing body of evidence suggests that carcinosarcomas arise from a precursor epithelial cell with transformation into sarcomatous components (McCluggage, 2002). Accordingly, gynecologic carcinosarcomas are managed as aggressive carcinomas rather than sarcomas (Berton-Rigaud et al., 2014). The carcinoma and sarcomatous components share common somatic mutations (Zhao et al., 2016; Cherniack et al., 2017). However, there is also intercomponent heterogeneity, e.g., in epithelial to mesenchymal transition (EMT) related genes, with greater heterogeneity noted in more advanced or aggressive cases (Liu et al., 2018). Examples of relevant genes include epithelial markers such as E-cadherin, mesenchymal markers such as vimentin, and transcription factors such as Slug and Snail. Understanding the differences between the epithelial and mesenchymal components may help us to understand the lineage-specific biology of these difficult-to-treat cancers and target treatments more effectively.

⁎⁎ Corresponding author at: The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2050 Chicago, IL 60637.
E-mail address: kkurnit@bsd.uchicago.edu (K.C. Kurnit).

https://doi.org/10.1016/j.gore.2022.100987
Received 10 March 2022; Received in revised form 21 April 2022; Accepted 24 April 2022
Available online 27 April 2022
2352-5789/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Glucocorticoid receptor (GR) signaling is increasingly recognized as an important mediator of solid tumor biology and is expressed to varying degrees in many carcinomas (Block, 2017). Its impact on tumor behavior is extremely context dependent. For example, high GR expression in estrogen receptor (ER)-positive breast cancer is associated with cell differentiation, decreased proliferation, and better clinical outcomes (West et al., 2016), whereas in ER-negative breast cancer high GR expression is correlated with EMT-associated gene expression, de-differentiation, and a poor prognosis (Pan et al., 2011). In preclinical studies of castrate-sensitive prostate cancer, GR activation appears to slow disease progression, but when prostate cancer becomes castrate-resistant, GR signaling drives more aggressive disease (Kach et al., 2015). Similarly, recent data suggest that GR signaling becomes increasingly important in driving metastases as breast cancer becomes more advanced (Obradović et al., 2019). Increased GR expression correlates with poor outcomes in both endometrial cancer (Tangen et al., 2017) and ovarian cancer (Veneris et al., 2017). Information about the other hormonal receptors was not available for the study in ovarian cancer patients, but among the endometrial cohort, this poor prognosis was somewhat ameliorated in the presence of positive estrogen, progesterone, or androgen receptor expression. Based on the observed association of EMT with GR expression in other estrogen and progesterone receptor (PR) negative cancers, as well as prior research demonstrating GR expression in sarcomas (Block, 2017), we hypothesized that tumor cells in the sarcomatous regions of carcinosarcoma would have higher GR expression and lower ER/PR expression, while the carcinoma cells would express relatively decreased GR and higher ER and PR expression.

2. Methods

2.1. Patient specimens

Archival primary Mullerian carcinosarcoma specimens were retrieved from patients diagnosed at The University of Chicago between May 2009 and August 2014 using the in-house ovarian cancer database (Institutional Review Board [IRB] 13372B) (Sawada et al., 2007) and a
A retrospective review of endometrial specimens under a separate protocol (IRB 18-1837). All specimens were evaluated by a gynecologic pathologist (RL) to confirm the diagnosis using H&E staining.

### 2.2. Immunohistochemistry (IHC)

Four-micron sections were cut from formalin-fixed paraffin-embedded (FFPE) whole tissue sections. Standard techniques were used to stain tissue sections for estrogen receptor (Leica Biosystems, mouse IgG1 clone 6F11, 1:60 dilution), progesterone receptor (Leica Biosystems, mouse IgG1 clone 16, 1:300 dilution), androgen receptor (Leica Biosystems, mouse IgG clone AR441, 1:250 dilution), and GR (Leica Microsystems, rabbit IgG Cat#3660, dilution 1:1500). One pathologist (RL) reviewed the IHC slides. Receptor expression was quantified using the H-score, as previously described (Block, 2017). H-score is a commonly used expression assessment tool which takes into account both staining intensity and staining frequency throughout the tumor. Staining intensity was interpreted as none (0), weak (1+), moderate (2+), and strong (3+). Percentage of component staining was scored as a continuous variable from 0 to 100%. H-score was calculated by multiplying staining intensity by percentage of cells with staining (range: 0–300).

### 2.3. Statistical analysis

H-scores for the sarcomatous and carcinomatous components of the specimens were compared using a Wilcoxon signed-rank test. Statistical significance was defined as $p < 0.05$.

### 3. Results

Eight endometrial carcinosarcomas and ten ovarian carcinosarcomas were identified. An example of GR, ER, PR, and androgen receptor tissue staining is shown in Figs. 1 and 2. Table 1 summarizes the differences in
nuclear receptor expression between the sarcomatous and carcinomatous components of tumors. Overall, mean GR H-score was significantly increased in the sarcomatous component when compared to the carcinomatous component of tumors (144.4 vs 38.9, Wilcoxon test, \( p = 0.002 \)). A summary of differences in receptor expression by tumor type is also listed in Table 1.

Expression of the other steroid hormone receptors also differed between the sarcomatous and carcinomatous components, with estrogen, progesterone, and androgen receptors all higher in the carcinomatous component than the sarcomatous component. The mean estrogen receptor H-score was 3.1 in the sarcomatous components versus 63.1 in the carcinomatous components (Wilcoxon test, \( p = 0.002 \)). Mean progesterone receptor H-score was 1.7 in the sarcomatous components, versus 47.2 in the carcinomatous components (Wilcoxon test, \( p < 0.001 \)). Androgen receptor expression was low overall and not expressed in the sarcomatous component of any tumor, resulting in a mean androgen receptor H-score of 0 in the sarcomatous components and 2.8 in the carcinomatous components (Wilcoxon test, \( p = 0.04 \)).

### Table 1

| Component                      | GR H-score | ER H-score | PR H-score | AR H-score |
|-------------------------------|------------|------------|------------|------------|
| **Overall**                   |            |            |            |            |
| Sarcomatous mean (range)      | 144.4 (0–300) | 3.1 (0–50) | 1.7 (0–20) | 0 (0–0)    |
| Carcinomatous mean (range)    | 38.9 (0–160) | 63.1 (0–300) | 47.2 (0–210) | 2.8 (0–0) |
| Mean of differences (range)   | 105.6 (70–300) | 60 (270–5) | 45.6 (210–0) | 0 (20–0) |
| 95% Confidence Interval       | 47.3–163.8 | –107.4 to –12.6 | –74.7 to –16.5 | –5.6 to –0.1 |
| P-value                       | 0.002 | 0.002 | <0.0001 | 0.04 |
| **Ovarian**                   |            |            |            |            |
| Sarcomatous mean (range)      | 185 (10–300) | 0.5 (0–50) | 3 (0–20) | 0 (0–0) |
| Carcinomatous mean (range)    | 68 (10–160) | 96.5 (0–300) | 63 (0–210) | 4 (0–0) |
| Mean of differences (range)   | 117 (70–290) | –91.5 (270–0) | –60 (210–0) | –4 (20–0) |
| 95% Confidence Interval       | 29.5 to –173.9 | –111.9 to –9.0 | 1.0 |
| P-value                       | 0.01 | 0.008 | 0.007 | 0.08 |
| **Uterine**                   |            |            |            |            |
| Sarcomatous mean (range)      | 93.8 (0–300) | 0.6 (0–5) | 0 (0–0) | 0 (0–0) |
| Carcinomatous mean (range)    | 2.5 (0–20) | 21.3 (0–120) | 27.5 (0–90) | 1.3 (0–10) |
| Mean of differences (range)   | 91.3 (0–300) | –20.6 (40–5) | –27.5 (90–0) | –1.3 (10–0) |
| 95% Confidence Interval       | –6.5 to –56.2 to –52.3 to –4.2 to | 189 (15.0) | 2.7 | 1.7 |
| P-value                       | 0.005 | 0.11 | 0.005 | 0.38 |

Legend:
GR = glucocorticoid receptor; ER = estrogen receptor; PR = progesterone receptor; AR = androgen receptor.

H-score was calculated by multiplying staining intensity (0 to 3 + ) by percentage of cells (0 to 100%) with staining.

p-value: computed using t-tests.

4. Discussion

The present study is the first to assess GR expression in carcinosarcomas of Mullerian origin. Carcinosarcomas are one model for epithelial-mesenchymal transition (Zhao et al., 2016), with increased expression of EMT-associated genes in the sarcomatous component of carcinosarcomas relative to the carcinomatous component. Although most likely derived from a single progenitor cell, the two compartments do have some important differences. It is also worth noting that the trend for expression differences of each of the receptors in the carcinoma versus sarcoma components were similar in the uterine and ovarian tumors; e.g., glucocorticoid receptor expression was higher in the sarcoma component, and estrogen, progesterone, and androgen receptors were higher in the carcinoma component. Our results add to that growing body of literature by highlighting differences in glucocorticoid receptor expression, which has not been previously explored, and which could have both mechanistic and therapeutic implications.

Recent molecular evaluations have highlighted the role that EMT plays in the evolution from carcinomatous to sarcomatous features. One recent study performed whole exome sequencing on 41 Mullerian carcinosarcomas (Zhao et al., 2016). Multiregion whole-exome sequencing was performed in six of these tumors in order to investigate their origins. In these tumors, the sarcomatous and carcinomatous components were analyzed separately, confirming a common, epithelial precursor lesion. Along with identification of many common mutations among epithelial ovarian and endometrial carcinomas, these sequencing data also demonstrated a significant number of alterations among histone genes, including several that were previously unrecognized. The authors hypothesize that these changes may contribute to some of the differential expression in the carcinomatous and sarcomatous components, and to the EMT that is seen in these tumors (Zhao et al., 2016). In laboratory data from triple-negative breast cancer, GR expression and activity also appear to drive EMT-associated gene expression (Pan et al., 2011). In this preclinical study, ER-negative breast cancer cell lines were treated with dexamethasone and 187 glucocorticoid receptor direct target genes were identified. Using gene enrichment pathway analysis, functional pathways associated with glucocorticoid receptor activation were identified. One of the top 10 pathways associated with activation was that associated with regulation of EMT. Extrapolating from those data, we speculate that GR may similarly act as a transcriptional driver of EMT in the transformation of carcinomatous to sarcomatous cells in these interesting tumors.

Whereas glucocorticoid receptor expression was upregulated, estrogen receptor and progesterone receptor were relatively decreased in the sarcomatous component of carcinosarcomas. We hypothesize that one of the key events leading to aggressive disease in hormone-driven cancer may be the upregulation of glucocorticoid receptor. However, it remains unclear whether it is glucocorticoid upregulation on its own, or glucocorticoid receptor upregulation in the context of downregulation of other hormonal receptor expression. In addition to the potential prognostic and mechanistic implications, GR expression may also represent a potential therapeutic target (Kach et al., 2015) for patients with carcinosarcomas. Given the relative chemotherapy-resistance of carcinosarcomas, identifying new treatment options for this subset of patients is critical. Studies testing GR antagonists as chemotherapy-sensitizing agents have been developed. Preliminary data from a Phase II study of relacorilant, a selective GR modulator, demonstrated an improvement in median progression-free survival for patients with platinum-resistant ovarian cancer who received the combination of intermittent relacorilant and nab-paclitaxel over nab-paclitaxel alone (5.6 months versus 3.8 months, \( p < 0.05 \)) (Colombo et al., 2021). Preclinical data suggest that the combination of paclitaxel and a glucocorticoid receptor antagonist may also be worthy of investigation in pancreatic cancer and breast cancer patients (Greenshtein and Hunt, 2021; Skor et al., 2013). Future studies should elucidate the mechanistic role that high GR expression and activity may play in the aggressive nature of these gynecologic cancers, with the hope that new treatment strategies can be tested.

### Funding

GGF, SDC, SJW, and EL acknowledge support from the Mayo Clinic.
SPORE in Ovarian Cancer Developmental Research Program, Pilot Study Award (5P50CA136393-09); SDC and GFF received funding from NIH R21CA223426-02. KCK, MS, JTV, RRL, EL, GFF acknowledge support from the University of Chicago Comprehensive Cancer Center Core Immunohistochemistry Facility, grant #5P30CA014599-46.

CRediT authorship contribution statement

Katherine C. Kurnit: Writing – original draft, Writing – review & editing, Data curation, Validation, Visualization. Meghan Steiner: Writing – original draft, Visualization. Ricardo R. Lastra: Investigation, Writing – review & editing, Visualization. S. John Weroha: Writing – review & editing, Visualization. John Cursio: Formal analysis, Writing – review & editing. Ernst Lengyel: Writing – review & editing, Resources. Gini F. Fleming: Investigation, Conceptualization, Methodology, Writing – review & editing, Resources, Supervision. Suzanne D. Conzen: Investigation, Conceptualization, Methodology, Writing – review & editing, Resources, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Acknowledgments

The authors would like to acknowledge Dr. Jennifer Veneris for her contributions to this work. Ernst Lengyel receives research funding from AbbVie and Arsenal Bio to perform translational ovarian cancer research that is completely unrelated to this study. Suzanne Conzen is an inventor on patents licensed by The University of Chicago to Corcept Therapeutics regarding a method to use glucocorticoid receptor modulators as therapies for triple-negative breast cancer and prostate cancer that is not directly relevant to Mullerian carcinosarcomas. Gini Fleming has served on an advisory board to GS KP on a topic not directly related to this study.

References

Berton-Rigaud, D., Devouassoux-Shisheboran, M., Ledermann, J.A., Leizao, M.M., Powell, M.A., Poveda, A., Beole, P., Glasspool, R.M., Crouttsberg, C.L., Harter, P., Kim, J.W., Reed, N.S., Ray-Coquard, I., 2014. Gynecologic Cancer InterGroup (GGIG) consensus review for uterine and ovarian carcinosarcoma. Int. J. Gynecol. Cancer 24 (Supp 3), S55–S60.

Matsumoto, K., Takazawa, Y., Rosi, M.S., Eliahou, E., Yunokawa, M., Sheridan, T.B., Bush, S.H., Kobocista, M.M., Blake, E.A., Takano, T., Basta, T., Sato, S., Shida, M., Ibeda, Y., Adachi, S., Yokoyama, T., Takekuma, M., Yanai, S., Takeuchi, S., Nishimura, M., Iwasaki, K., Johnson, M.S., Yoshida, M., Hakam, A., Machida, H., Mhawech-Fauceglia, P., Ueda, Y., Yoshino, K., Kajiwara, H., Hasegawa, K., Yasuda, M., Miyake, T.M., Moriya, T., Yuba, Y., Morgan, T., Fukagawa, T., Pejovic, T., Nagano, T., Sasaki, T., Richmond, A.M., Post, M.D., Shahzad, M.M.K., Im, D.D., Yoshida, H., Enomoto, T., Omatsu, K., Ueland, P.R., Kelley, J.L., Karabshbajian, R.G., Roman, L.D., 2018. Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. Ann. Surg. Oncol. 25 (12), 3676–3684.

McCluggage, W.G., 2002. Malignant biphasic uterine tumors: carcinosarcoma or metaplastic carcinoma? J. Clin. Pathol. 55 (5), 321–325.

Zhao, S., Bellone, S., Lopez, T., Thakral, D., Schwab, C., English, D.P., Black, J., Cocco, E., Choi, J., Zammataro, L., Predolini, F., Bonazolli, E., Bi, M., Buza, N., Hui, P., Wong, S., Abu Khalil, M., Ravaggi, A., Bignotti, E., Bandiera, E., Romani, C., Todeschini, P., Tani, R., Zanotti, L., Odicino, F., Pecorelli, S., Donzelli, C., Ardighieri, L., Facchetti, F., Falchetti, M., Silasi, D.-A., Ratner, E., Azodi, M., Schwartz, P.E., Man, S., Angioli, R., Terranova, C., Quick, C.M., Ehrlich, B., Biliquist, K., Lee, M., Choi, M., Stieger, A.L., Boggan, T.J., Schlessinger, J., Liffon, R.P., Santin, A.D., 2016. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A. 113 (43), 12238–12243.

Chermnick, A.D., et al., 2017. Integrated molecular characterization of uterine Carcinosarcoma. Cancer Cell 31 (3), 411–423.

Liu, Y., Weber, Z., San Lucas, F.A., Deshpande, A., Jakubek, Y.A., Sulaiman, R., Fagerness, M., Flier, N., Sulaiman, J., Davis, C.M., Fowler, J., Starks, D., Rojas, H., Espallart, L., Lazar, A.J., Davies, G.E., Ebli, E.A., Scher, P., 2018. Assessing inter-component heterogeneity of biphasic uterine carcinosarcoma. Gynecol. Oncol. 151 (2), 243–249.

Block, T.S., et al., 2017. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. CancerManag Res. 9, 65–72.

West, D.C., Pan, T., Tonsing-Carter, E.Y., Hernandez, K.M., Fernandez, J., Wang, X., Sendeckyj, E., 2021. 721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves Breast Cancer Outcome. Mol. Cancer Res. 14 (8), 707–719.

Pan, D., Kocherginsky, M., Conzen, S.D., 2011. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 71 (20), 6360–6370.

Kach, J., Conzen, S.D., Szumalewitz, R.Z., 2015. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci. Transl. Med. 7 (305), p. 305pe19.

Obradovi´c, M.M.S., Hamelin, B., Manevski, N., Couto, J.P., Sethi, A., Coisieux, M.-E., Münster, S., Okamoto, R., Kohler, H., Schmidt, A., Bentres-Adj, M., 2019. Glucocorticoids promote breast cancer metastasis. Nature 567 (7749), 540–544.

Tangen, I.L., Veneris, J.T., Halle, M.K., Werner, H.M., Trovik, J., Alden, L.A., Salvesen, H.B., Conzen, S.D., Fleming, G.F., Krakstad, C., 2017. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol. Oncol. 147 (3), 672–677.

Veneris, J.T., Darcy, K.M., Mhawech-Fauceglia, P., Tian, C., Lengyel, E., Lastra, R.R., Pejovic, T., Conzen, S.D., Fleming, G.F., 2017. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol. Oncol. 146 (1), 153–160.

Sawada, K., Radjabi, A.R., Shinomiya, N., Kistner, E., Kenny, H., Becker, A.R., Turkylilmaz, M.A., Salgia, R., Yamada, S.D., Vande Woode, G.F., Tretiakova, M.S., Lengyel, E., 2007. c-Met overexpression is a prognostic factor in ovarian cancer and is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer 106 (11), 2616–2627.

Bertin-Rigaud, D., Devouassoux-Shisheboran, M., Ledermann, J.A., Leizao, M.M., Powell, M.A., Poveda, A., Beole, P., Glasspool, R.M., Crouttsberg, C.L., Harter, P., Kim, J.W., Reed, N.S., Ray-Coquard, I., 2014. Gynecologic Cancer InterGroup (GGIG) consensus review for uterine and ovarian carcinosarcoma. Int. J. Gynecol. Cancer 24 (Supp 3), S55–S60.